1. Updates in Detection and Management of BCRPC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

4. BCRPC Overview

5. Defining BCRPC After RP

6. Defining BCRPC After RT

7. Case Patient Presentation

8. Case Patient PET Scans

9. Case Patient BCRPC Management

10. Pre-PET Clinical Implications of a Rising PSA

11. Pre-PET Diagnostic Evaluation of BCRPC

12. Advent of PC-Specific PET

13. NCCN PET Imaging Recommendations

14. 18F-NaF-PET/CT Overview of an Older PET Tracer

15. ACR Guidelines for Detecting Recurrence

16. Choline Overview

17. 11C-Choline PET/CT in Patients With BCRPC: Systematic Review

18. 11C-Choline PET/CT Sensitivity by PSA Level

19. 18F-Fluciclovine Overview

20. 18F-Fluciclovine PET/CT in BCRPC BED-001 Study

21. 18F-Fluciclovine PET/CT vs 11C-Choline PET/CT in BCRPC Prospective Trial

22. FALCON Trial Design

23. FALCON Trial Results

24. LOCATE Study Design and Detection Rates

25. LOCATE Study Change in Treatment

26. PSMA An Investigational PET Imaging Target

27. Example of 68Ga PSMA PET/CT

28. Bone Scintigraphy vs 18F-DCFPyL PET/CT

29. 68Ga PSMA PET Analysis of 2 Trials

30. 68Ga PSMA PET Analysis of 2 Trials (cont)

31. 68Ga PSMA vs Choline

32. Challenges in Identifying PC Recurrence at Low PSA Levels

33. PET/MRI in Recurrent PC After RP

34. New Studies on PSMA From AUA 2018

35. Moving From Improved Visualization to Improved Outcomes

36. Conclusion

37. Abbreviations

38. Abbreviations (cont)